I scribbled my signature on a pharmaceutical rep’s iPad last week for some samples of Jardiance, a diabetes drug that now has expanded indications, according to the US Food and Drug Administration.

This drug lowers blood sugar (reduces HbA1c by less than one point) but also reduces diabetes-related kidney damage, heart attacks, strokes and now also admission rates for heart failure (from 4.1% to 2.7% if I remember correctly).